Disease activity score 28-CRP (DAS28-CRP) at Week 4 is not improved by 15 mg (QD) acalabrutinib plus methotrexate (5.40; n=15) as compared to placebo plus methotrexate (5.05; n=15) in patients with RA. This evidence concerns the gene CRP and rheumatoid arthritis.